Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Indiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Indiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Indiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rashid Khan (NPI 1649446444)

Field	Value
Entity Type	Individual
Organization	Rashid Khan
Address	5340 Holy Cross Pkwy
City	Mishawaka
State	IN
ZIP	46545
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 1, 2008

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the clear revenue center: lifetime Medicare revenue is $1.5M while there is no Medicaid billing on file, making the practice effectively single‑payer (Medicare) in the claims data available. The absence of any Medicaid activity suggests payer-mix exposure is concentrated and that Medicaid-related contract or service lines are not present in this record.

Revenue is highly concentrated in a few drug and clinic visit codes: the precomputed top‑3 codes account for 69.9% of total Medicare revenue, led by J9271 at $791.2K (53.2%), followed by J0897 at $156.6K (10.5%), and 99214 at $92.6K (6.2%). This concentration indicates that a small set of high-cost drug administrations and associated E/M visits drive the majority of receipted Medicare dollars for this NPI.

The code mix indicates an oncology infusion–centric operation with a strong emphasis on immunotherapy and supportive biologics. J9271 (pembrolizumab) is the dominant revenue generator, and J0897 (denosumab) appears as the second‑largest drug line; chemotherapy administration codes such as 96413 ($40.1K, 2.7%) and infusion add‑ons like 96417 ($4.6K, 0.3%) further support an infusion/oncology practice model rather than a purely office‑visit clinic.

Competitive standing by code is mixed: J9271 ranks #485 of 1841 (73th percentile) and is characterized as "typical, unremarkable volume for this code," so the provider participates at a mid‑level nationally for pembrolizumab. J0897 ranks #1401 of 10057 (86th percentile) and is also labeled "typical, unremarkable volume for this code," indicating solid but not dominant denosumab activity; by contrast, 99214 ranks #10384 of 479517 (98th percentile) and is labeled "notably above typical national volume for this code," signaling unusually high E/M visit volume relative to national peers.

Operational throughput appears significant for infusion workflow: 96375 (907 claims, $10 avg, $10K revenue) ranks #202 of 5191 (96th percentile) and is labeled "notably above typical national volume for this code," which—together with high counts for 96365 and 96372—indicates frequent IV push and infusion procedures and supports the need for robust infusion staffing and supply capacity. Multiple administration codes appearing in the top lines point to a practice oriented around repeated drug administrations rather than episodic consults alone.

Imaging and diagnostic support are a meaningful portion of revenue but secondary to drug administration: 78815 (PET/CT) generated $87.6K (5.9%) and ranks in the midrange nationally (59th percentile, "typical, unremarkable volume for this code"), while CT abdomen/pelvis 74177 contributed $17.9K (1.2%). This pattern suggests integrated use of advanced imaging to guide oncology care rather than imaging as a primary revenue driver.

Tenure and stability in the market are evident: the NPI was enumerated on 2008-05-01 (~18 years ago), indicating a long-established billing presence under this provider identifier. Combined with concentrated Medicare revenue and repeated high-frequency administration codes, the record is consistent with a stable oncology clinician operating an infusion-focused service line.

Several codes show above‑peer percentiles for supportive and infusion activity even when labeled "typical" for volume, and a few (notably 96375 and 99214) are explicitly flagged as "notably above typical national volume for this code." These mixed signals—very high E/M and infusion administration percentiles alongside drug volumes that are mid‑range nationally—suggest the provider has higher encounter and infusion throughput relative to many peers while drug utilization patterns are within more common national ranges.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

54 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,400	$40	$791.2K
J0897	Injection, denosumab, 1 mg	8,700	$20	$156.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,040	$90	$92.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,150	$87.6K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	33,900	$1	$67.8K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,070	$30	$66.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$90	$40.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	500	$60	$28.8K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	280	$90	$25.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	180	$110	$20.3K

Showing 1–10 of 54

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 54 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Indiana Distribution

Rashid Khan — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Indiana

Full comparison — all codes billed, vs. state median

54 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	20	11,200	$40	$631.7K
J1568	3	10	2,690	$30	$97.5K
J0897	25	220	2,730	$20	$74.9K
J0881	2	10	20,080	$1	$47.4K
78815	51	140	60	$300	$26.6K
Q5108	3	10	310	$80	$24.6K
J9217	60	90	150	$130	$23K
96413	12	120	140	$90	$19.1K
99214	137	10,540	110	$80	$15.5K
J3490	15	40	50	$180	$12.8K

Showing 1–10 of 54

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rashid Khan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Woodlawn Hospital	IN	Critical Access Hospital	$0	$5.3M
Michiana Hematology-oncology P C	IN	Medical Oncology Physician	$0	$3M
Mohamed Farhat	IN	Medical Oncology Physician	$2.2M	$0
Eduardo Braun	IN	Medical Oncology Physician	$1.8M	$0
Bilal Ansari	IN	Medical Oncology Physician	$1.7M	$0
Brion Shin	TN	Radiation Oncology Physician	$1.5M	$0
Binh Tran	IN	Radiation Oncology Physician	$1M	$0
Sayuri Cheruvu	IN	Medical Oncology Physician	$934.1K	$0
Muhammad Hussain	IN	Medical Oncology Physician	$932.8K	$0
Jose Bufill	IN	Medical Oncology Physician	$765.9K	$0

Nearby Providers

Other providers in the same ZIP code as Rashid Khan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Saint Joseph Regional Medical Center-south Bend Campus, Inc.	IN	General Acute Care Hospital	$0	$18.7M
Toxusa Labs LLC	IN	Clinical Medical Laboratory	$1.3M	$9.6M
Pic Indiana PC	IN	Urgent Care Clinic/Center	$0	$10.7M
Radiology, Inc	IN	Diagnostic Radiology Physician	$0	$6.8M
Miracle Lane Family Dentistry P.C.	IN	Dental Clinic/Center	$0	$5.1M
Michiana Eye Center LLC	IN	Ophthalmology Physician	$0	$5M
Saint Joseph Regional Medical Center-south Bend Campus, Inc.	IN	Family Medicine Physician	$0	$4.8M
Northern Indiana Interim Healthcare Company LLC	IN	Home Health Agency	$0	$4.5M
Del Pilar Medical & Urgent Care PC	IN	Geriatric Medicine (Family Medicine) Physician	$0	$3.6M
Linda Monroe	IN	Clinical Psychologist	$15.4K	$2.9M

Rashid Khan — Billing Profile & Reimbursement Data

Sign up for Rashid Khan — Billing Profile & Reimbursement Data policy alerts

Rashid Khan — Billing Profile & Reimbursement Data

Sign up for Rashid Khan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References